Study drug TTX-080 for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This Phase 1 study tests TTX-080, a drug designed to block a cancer immune “signal” (HLA-G) to help the body fight advanced colorectal cancer. It mainly checks safety and how the treatment works in people with cancer that has spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic colorectal cancer (enrolling for CRC only).
- You are 18 years or older and can give informed consent.
- Your cancer has measurable disease that can be tracked on scans or tests.
- Your overall functioning is good (ECOG 0–1) and you’re expected to live at least 12 weeks.
- You have no history of severe allergic reactions to similar medicines (especially monoclonal antibodies).
- You have not taken another experimental (investigational) treatment within the last 28 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation therapy, an immunotherapy drug (QL1706), and two targeted drugs (TAS-102 and bevacizumab) for people with advanced colorectal cancer that has spread and is not removable by surgery. It aims to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a new immunotherapy drug (STC-1010) for people with colorectal cancer that cannot be removed by surgery or has spread. It aims to see if the drug can shrink tumors or slow the disease.
This trial tests a new drug, TQB2930, combined with chemotherapy (with or without bevacizumab) for advanced colorectal cancer that cannot be removed by surgery. It's designed for people whose tumors are HER2-positive and have not responded to standard treatments.
This trial is testing a new combination of drugs (envafolimab, cetuxima-β, and chemotherapy) for people with a specific type of advanced colorectal cancer that has not been treated yet. The goal is to see if it is safe and works well.
This Phase 2 trial tests whether bevacizumab plus oxaliplatin and TAS-102 works better and is safe as the first treatment for advanced colorectal (colon/rectum) cancer. You may be asked to meet specific health and blood-test requirements and avoid other cancer treatments during the study.
This trial tests a new drug combination for people with advanced colorectal cancer that cannot be removed by surgery. It aims to see if the treatment can shrink tumors and help patients live longer.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.